The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2023 | Real-world experiences with toxicity in patients treated with CAR-T cell therapy
Eleni Gavriilaki, MD, PhD, G. Papanikolaou Hospital, Thessaloniki, Greece, discusses real-world data (RWD) on the toxicities observed in patients treated with various CAR-T cell therapies, and further highlights the importance of increasing awareness and obtaining RWD in this space. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
EG has received research funding and honoraria from Gilead.
